Amolyt Pharma Announces Abstracts Accepted for Presentation

LYON, France and CAMBRIDGE, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced

Related Keywords

Turkey , Chicago , Illinois , United States , Istanbul , France , Cambridge , Cambridgeshire , United Kingdom , Jordyn Temperato , Amolyt Pharma , Ashley Robinson , Twitterand Linkedin , Rapid Communications , European Congress , Lifesci Communications , Endocrine Society Meeting , Lifesci Advisors , Koral Communications , Society Meeting , Has No Impact , Bone Parameters Following Chronic Treatment , Oral Presentation , Induces Rapid Reduction , Urinary Calcium , Chronic Hypoparathyroid , Rapid Oral Presentation , Chronic Hypoparathyroidism , Rapid Oral , Amino Acid Peptide Antagonist , Human Growth Hormone Receptor , Effectively Suppresses , Beagle Dogs , Rapid Communication , Repeated Treatment , Induces Enhanced Suppression , Poster Presentation , Growth Hormone , Relevant Biology , Clinical Practice Patterns , Mineral Metabolism , Sci Advisors , Amolyt , Dharma , Nnounces , Abstracts , Accepted , Presentation , Undo ,